Headlines about Anthera Pharmaceuticals (NASDAQ:ANTH) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Anthera Pharmaceuticals earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 47.1064115723117 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the media stories that may have impacted Accern’s scoring:

Several brokerages have recently weighed in on ANTH. Jefferies Group LLC reiterated a “hold” rating and set a $1.75 target price (down from $2.25) on shares of Anthera Pharmaceuticals in a research report on Friday. ValuEngine lowered shares of Anthera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Zacks Investment Research lowered shares of Anthera Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. Anthera Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $10.11.

Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) opened at 1.31 on Tuesday. The firm’s market capitalization is $13.20 million. The stock’s 50 day moving average is $1.49 and its 200 day moving average is $1.15. Anthera Pharmaceuticals has a 12 month low of $1.20 and a 12 month high of $28.40.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.09) by $1.12. Equities research analysts forecast that Anthera Pharmaceuticals will post ($3.88) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/anthera-pharmaceuticals-anth-earns-media-sentiment-score-of-0-20/1490532.html.

Anthera Pharmaceuticals Company Profile

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Insider Buying and Selling by Quarter for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.